Delay of Alternative Antiviral Therapy and Poor Outcomes of Acyclovir-Resistant Herpes Simplex Virus Infections in Recipients of Allogeneic Stem Cell Transplant

Acyclovir is commonly used to prevent and treat herpes simplex virus (HSV) reactivation after hematopoietic cell transplant (HCT), and only few reports have been published on acyclovir-resistant HSV in HCT recipients. We reviewed the medical records of patients with a microbiologic diagnosis of acyc...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Transpl Int
Autores principales: Ariza-Heredia, Ella J., Chemaly, Roy F., Shahani, Lokesh R., Jang, Ying, Champlin, Richard, Mulanovich, Victor E.
Formato: Artigo
Lenguaje:Inglês
Publicado: 2018
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5948153/
https://ncbi.nlm.nih.gov/pubmed/29464765
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/tri.13142
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares